AGENDA
(For Spring 2020 Oncology Meeting)
Infectious Disease Final Agenda To Be Announced June 1, 2020.
TUESDAY, MARCH 31
8:30am // OPENING REMARKS
8:40am // TALK - RALPH PARCHMENT, NCI, MANAGING DIRECTOR, DCTD PROGRAM IN PHARMCODYNAMIC BIOMARKERS
9:10am // KEYNOTE TALK - BRIAN LELAND-JONES (FRM DIRECTOR OF THE EMORY AND MCGILL CANCER CENTERS)
Transformation in Cancer Diagnosis and Treatment 2020
09:40am // Corporate Presentation - OTraces
10:00am // Corporate Presentation - Travera
10:20am // Corporate Presentation - Ovensa
10:40am // Corporate Presentation - Kineta
11:00am // Corporate Presentation - Flow Pharmaceuticals
11:20am // Corporate Presentation - Modra Pharmaceuticals
11:40am // Corporate Presentation - SciTech
12:00pm // Corporate Presentation - Onconova Therapeutics
12:20 pm // Corporate Presentation - Ehmet Health
12:40 pm // Corporate Presentation - Telexos
1:00pm // CFIUS TALK
Robbin Goodman, Director of Business Affairs, George H. W. Bush Foundation for U.S.-China Relation
1:15pm // Corporation Presentation - Katena Oncology
1:35pm // Corporation Presentation - Canget BioTekpharma
1:55pm // Corporation Presentation - Creatv Microtech
2:15pm // Corporation Presentation - Jubilant Life Sciences
2:35pm // Corporation Presentation - LifeBridge 1000
2:55pm // Corporation Presentation - GenEndeavor
3:15pm // Corporation Presentation - ENB Therapeutics
3:35pm // Corporation Presentation - Lightpoint Medical
3:55pm // Corporation Presentation - TomoWave Laboratories
4:15pm // BREAK
4:30pm // Corporation Presentation - SynDevRx
4:50pm // Corporation Presentation - Ziteo Medical
5:10pm // Corporation Presentation - OncoSynergy
5:30pm // Corporation Presentation - Vitanova Biomedical
5:50pm // SPEAKER - Fred Nazem, Former CEO/Chairman Oxford Health, GP of 7 Venture Funds
EVOLUTION OF LIFE SCIENCE VENTURE CAPITAL FROM 1970-2020
6:15pm // Corporation Presentation - Rejuvenan
6:35pm // CLOSING REMARKS
WEDNESDAY, APRIL 1
8:00am // OPENING REMARKS
8:10am // PANEL - HOW COVID-19 WILL INFLUENCE ONCOLOGY CLINICAL TRIALS
Moderator: Roy Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology,
Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director for Translational Research, Yale Cancer Center
Panelist: Mario Sznol, MD (panel role: oncologist, Professor of Medicine (Medical Oncology); Co-Leader, Cancer Immunology, Yale Cancer
Center; Co-Director, Yale SPORE in Skin Cancer
Brinda Emu, MD (panel role: virologist), Assistant Professor of Medicine (Infectious Diseases), Yale School of Medicine
Paolo A. Ascierto, MD (panel role: oncologist), Vice-Director of the Unit of Melanoma, Cancer Immunotherapy and Innovative
Therapy Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute
Fondazione G. Pascale, Naples, Italy
8:40am // KEYNOTE - COVID: OUR LIFE SCIENCES SPUTNIK MOMENT
Dr. Ronald DePinho, Former President, MD Anderson Cancer Center
9:10am // Corporate Presentation - Impact Therapeutics
9:30am // Corporate Presentation - Summit Biomedical Imaging
9:50am // Corporate Presentation - Incysus
10:10am // Corporate Presentation - Imagion
10:30am // Corporate Presentation - Qrono
10:50am // Corporate Presentation - LeadInvent Pharma
11:10am // Corporate Presentation - Diverse Biotech
11:30am // Corporate Presentation - NeoTherma
11:50am // Corporate Presentation - Oleander Medical Technologies
12:10am // Corporate Presentation - Aro Biotherapeutics
12:30pm // LUNCH TALK - APPLYING FINANCIAL ENGINEERING TO CANCER
Dr. Andrew Lo, Director, Laboratory for Financial Engineering, MIT
1:00pm // Corporate Presentation - AHEAD Medicine
1:20pm // Corporate Presentation - Promaxo
1:40pm // Corporate Presentation - Cybrexa Therapeutics
2:00pm // Corporate Presentation - iMedis
2:20pm // Corporate Presentation - My Personal Therapeutics
2:40pm // Corporate Presentation - Glysantis
3:00pm // Corporate Presentation - ImmuneCyte Life Sciences
3:20pm // KEYNOTE - NORMAL AND NEOPLASTIC STEM CELLS
Dr. Irving Weissman, Director, Institute for Stem Cell Biology & Regenerative Medicine AND Stanford Ludwig Center for Cancer Stem Cell Research and Medicine
4:00pm // SPECIAL TALK - HOW PRIVATE SECTOR FUNDS CAN ADD LIQUIDITY, ENABLE, AND SHIFT RISK IN GOVERNMENTAL HEALTHCARE
PURCHASES DURING THE COVID CRISIS
Doug Monticciolo, CEO and Founder, Brevet Capital (A Global Leader in Impact Investment)
4:10pm // Corporate Presentation - GlycoMantra
4:30pm // Corporate Presentation - LeadInvent Pharma
4:50pm // Corporate Presentation - Decoy Biosystems
5:10pm // Corporate Presentation - Geneius Biotechnology
5:30pm // Corporate Presentation - SageMedic
5:50pm // Corporate Presentation - Apricity
6:10pm // Corporate Presentation - Tvardi
6:30pm // CLOSING REMARKS